Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9262111 | 1.00 | ALDH1A1 (0.36) | ALDH1A1HSD17B10CES2CES1THRB | |
| SCHEMBL5188 | 1.00 | — | — | |
| SCHEMBL7589647 | 1.00 | ALDH1A1 (0.36) | ALDH1A1HSD17B10CES2CES1THRB | |
| SCHEMBL2081 | 1.00 | — | — | |
| SCHEMBL15121489 | 1.00 | ALDH1A1 (0.36) | ALDH1A1HSD17B10CES2CES1THRB | |
| SCHEMBL16694147 | 1.00 | ALDH1A1 (0.36) | ALDH1A1HSD17B10CES2CES1THRB | |
| SCHEMBL5429 | 1.00 | — | — | |
| SCHEMBL3030900 | 1.00 | ALDH1A1 (0.36) | ALDH1A1HSD17B10CES2CES1THRB | |
| SCHEMBL21831576 | 1.00 | ALDH1A1 (0.36) | ALDH1A1HSD17B10CES2CES1THRB | |
| SCHEMBL447244 | 1.00 | ALDH1A1 (0.36) | ALDH1A1HSD17B10CES2CES1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | claimed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | claimed |
| EP-3597670-B1 | WATER-SOLUBLE COMPOSITION, PRODUCTION METHOD FOR CURED PRODUCT THEREOF, AND CURED PRODUCT THEREOF, AND ACYL PHOSPHINATE | ADEKA CORP (JP) | 2024-07-10 | — | — | EP | disclosed |
| CN-118103209-A | Composition for forming release layer, laminate, and method for producing laminate | 日产化学株式会社 | 2024-05-28 | — | — | CN | disclosed |
| US-11958802-B2 | Migration-resistant photopolymerization sensitizer | KAWASAKI KASEI CHEMICALS LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-114616254-B | Acylphosphine composition, polymerization initiator, polymerizable composition, cured product, and method for producing same | 株式会社ADEKA | 2024-03-15 | — | — | CN | disclosed |
| EP-4306527-A1 | SN-38 DERIVATIVE, NANO-PARTICLES CONTAINING SAID DERIVATIVE, MEDICINE, AND METHOD FOR PRODUCING SAID NANO-PARTICLES | Japan Science and Technology Agency (JP) | 2024-01-17 | — | — | EP | disclosed |
| CN-113166554-B | xanthene compounds | 株式会社艾迪科 | 2023-12-12 | — | — | CN | disclosed |
| CN-117015545-A | SN-38 derivative, nanoparticle comprising the derivative, medicine, and method for producing the nanoparticle | 国立研究开发法人科学技术振兴机构 | 2023-11-07 | — | — | CN | disclosed |
| WO-2023199738-A1 | COMPOSITION AND CURED PRODUCT | 株式会社ADEKA | 2023-10-19 | — | — | WO | disclosed |
| EP-4261830-A1 | NOVEL PEPTIDOMIMETIC COMPOUND AND DESIGN | Oita University Institute of Advanced Medicine, Inc. (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-5384425-A | Diurea derivatives useful as medicaments and processes for the preparation thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-01-24 | — | — | US | disclosed |
| EP-0325397-B1 | DIUREA DERIVATIVES USEFUL AS MEDICAMENTS AND PROCESSES FOR THE PREPARATION THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-08-18 | — | — | EP | disclosed |
| US-5227492-A | Anticholesterol agents | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| US-5166429-A | Enzyme inhibitors of acylcoenzyme A cholesterol transferase as anticholesterol agents or antideposit agents | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| US-5091419-A | Anticholesterol agent | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-02-25 | — | — | US | disclosed |
| EP-0325397-A1 | Diurea derivatives useful as medicaments and processes for the preparation thereof | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1989-07-26 | — | — | EP | disclosed |
| US-4743295-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-05-10 | — | — | US | disclosed |
| US-4675045-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-06-23 | — | — | US | disclosed |
| US-4435404-A | ANTICOAGULANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958802-B2 | Migration-resistant photopolymerization sensitizer | F12, F10, PCNA | ALDH1A1 838/4885HSD17B10 130/4885CES2 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.